[go: up one dir, main page]

WO2009034431A3 - Formes posologiques à libération contrôlée de la varenicline - Google Patents

Formes posologiques à libération contrôlée de la varenicline Download PDF

Info

Publication number
WO2009034431A3
WO2009034431A3 PCT/IB2008/002311 IB2008002311W WO2009034431A3 WO 2009034431 A3 WO2009034431 A3 WO 2009034431A3 IB 2008002311 W IB2008002311 W IB 2008002311W WO 2009034431 A3 WO2009034431 A3 WO 2009034431A3
Authority
WO
WIPO (PCT)
Prior art keywords
varenicline
controlled
dosage forms
release dosage
antioxidant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/002311
Other languages
English (en)
Other versions
WO2009034431A2 (fr
Inventor
Barbara Alic Johnson
Kenneth Craig Waterman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of WO2009034431A2 publication Critical patent/WO2009034431A2/fr
Publication of WO2009034431A3 publication Critical patent/WO2009034431A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur une composition pharmaceutique à libération contrôlée de la varenicline ou d'un sel pharmaceutiquement acceptable de cette dernière, ladite composition pharmaceutique à libération contrôlée comprenant un enrobage et un antioxydant, l'antioxydant étant présent dans une quantité égale à un pourcentage en poids compris entre environ 0,1% et 55 de la couche d'enrobage.
PCT/IB2008/002311 2007-09-10 2008-08-29 Formes posologiques à libération contrôlée de la varenicline Ceased WO2009034431A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97101707P 2007-09-10 2007-09-10
US60/971,017 2007-09-10

Publications (2)

Publication Number Publication Date
WO2009034431A2 WO2009034431A2 (fr) 2009-03-19
WO2009034431A3 true WO2009034431A3 (fr) 2009-11-19

Family

ID=40032575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/002311 Ceased WO2009034431A2 (fr) 2007-09-10 2008-08-29 Formes posologiques à libération contrôlée de la varenicline

Country Status (1)

Country Link
WO (1) WO2009034431A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017119801A1 (fr) * 2016-01-08 2017-07-13 주식회사 씨티씨바이오 Préparation pharmaceutique à usage oral et goût masqué contenant de la varénicline ou un sel pharmaceutiquement acceptable de celle-ci
WO2018097629A1 (fr) * 2016-11-24 2018-05-31 에스케이케미칼 주식회사 Préparation à libération prolongée de varénicline et procédé pour sa production
GB2561333B (en) 2017-02-17 2020-06-03 Bo Soederpalm Treatment of alcohol use disorder
WO2018154395A2 (fr) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Composition pharmaceutique à libération contrôlée de varénicline
KR102235848B1 (ko) * 2019-11-20 2021-04-05 충북대학교 산학협력단 바레니클린 또는 이의 약학적으로 허용가능한 염의 지연 방출용 정제
WO2022271600A1 (fr) * 2021-06-25 2022-12-29 Handa Pharma, Inc. Formes posologiques stables de varénicline
CN115707688B (zh) * 2021-08-20 2025-05-16 威智医药股份有限公司 制备酒石酸伐尼克兰的原料中的杂质化合物及其制备、应用和检测方法
US20230056424A1 (en) * 2021-11-05 2023-02-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Prevention of the conversion of pharmaceutical agents into toxic n-nitrosamine compounds
WO2023012376A2 (fr) * 2021-11-05 2023-02-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Prévention de la conversion d'agents pharmaceutiques en composés de n-nitrosamine toxiques
EP4169516A1 (fr) * 2021-11-05 2023-04-26 Alfred E. Tiefenbacher (GmbH & Co. KG) Prévention de la conversion d'agents pharmaceutiques en composés n-nitrosamine toxiques
KR20230068877A (ko) * 2021-11-11 2023-05-18 주식회사 아울바이오 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물
CN114088843B (zh) * 2021-11-26 2024-01-30 上海皓鸿生物医药科技有限公司 一种伐伦克林中间体中亚硝胺类基因毒性杂质的检测方法
WO2023275413A2 (fr) * 2021-12-23 2023-01-05 Medichem, S.A. Formulations pharmaceutiques solides de varénicline

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235850A1 (en) * 2003-05-20 2004-11-25 Pfizer Inc Pharmaceutical compositions of varenicline

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4093105A (en) 1977-10-19 1978-06-06 N. T. Gates Company Plastic container with vent means
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US6133361A (en) 1996-02-03 2000-10-17 Mitsubishi Gas Chemical Company, Inc. Oxygen-absorbing composition, oxygen-absorbing resin composition, packing material, multi-layered packing, oxygen absorber packet, packing method and preservation method
WO1999001121A1 (fr) 1997-07-01 1999-01-14 Pfizer Inc. Sels de sertraline et formes posologiques de sertraline, a liberation prolongee
US6605610B1 (en) 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
HRP20050506A2 (en) 1997-12-31 2006-03-31 Pfizer Products Inc. Aryl fused azapolycyclic compounds
MXPA03001771A (es) 2000-08-30 2003-06-04 Pfizer Prod Inc Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
EP1243524A3 (fr) 2001-03-16 2004-04-07 Pfizer Products Inc. Trousse pharmaceutique pour médicaments sensibles a l'oxygène
KR20040063975A (ko) 2001-11-30 2004-07-15 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]-헥사데카-2(11)3,5,7,9-펜타엔의 약학 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235850A1 (en) * 2003-05-20 2004-11-25 Pfizer Inc Pharmaceutical compositions of varenicline

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KENNETH C WATERMAN ET AL: "N-methylation and N-formylation of a secondary amine drug (varenicline) in an osmotic tablet", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 97, no. 4, 1 April 2008 (2008-04-01), pages 1499 - 1507, XP008111696, ISSN: 0022-3549 *
PUZ MICHAEL J ET AL: "Use of the antioxidant BHT in asymmetric membrane tablet coatings to stabilize the core to the acid catalyzed peroxide oxidation of a thioether drug.", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY 2005, vol. 10, no. 1, 2005, pages 115 - 125, XP002546552, ISSN: 1083-7450 *
WATERMAN ET AL.: "N-methylation and N-formylation of a secondary amine drug (varenicline) in an osmotic tablet", J PHARM SCI, vol. 97, no. 4, 21 August 2007 (2007-08-21), pages 1499 - 1507, XP002546561, Retrieved from the Internet <URL:http://www3.interscience.wiley.com/journal/115805949/abstract?CRETRY=1&SRETRY=0> [retrieved on 20090909] *

Also Published As

Publication number Publication date
WO2009034431A2 (fr) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2009034431A3 (fr) Formes posologiques à libération contrôlée de la varenicline
WO2009113703A3 (fr) Préparation solide orodispersible
WO2011084593A3 (fr) Formulations empêchant un usage abusif
WO2009008006A3 (fr) Compositions pharmaceutiques d&#39;administration gastro-intestinale de médicaments
NZ600123A (en) Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
NZ610701A (en) Once daily formulation of lacosamide
WO2011039768A3 (fr) Compositions pharmaceutiques pour réduire une libération massive induite par l&#39;alcool
WO2009092129A8 (fr) Composition pharmaceutique de duloxétine à libération retardée
NZ589469A (en) Niacin and NSAID combination for reducing niacin-induced flushing
MX347753B (es) Formulaciones resistentes al abuso.
WO2008084698A1 (fr) Composition pharmaceutique à libération entretenue de tacrolimus
HRP20210618T1 (hr) Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom
WO2009059701A3 (fr) Comprimés à libération prolongée contenant de l&#39;hydromorphone
MX2011007779A (es) Formulaciones galenicas de compuestos organicos.
NZ589017A (en) Solid pharmaceutical formulation with delayed release
JP2013508289A5 (fr)
WO2008008592A3 (fr) Formulation multiparticulaire comprenant du tramadol sous forme à libération immédiate et à libération contrôlée
WO2008113901A3 (fr) Composition à libération prolongée de lévétiracetam et procédé de préparation.
WO2011141791A3 (fr) Formulations à libération prolongée de la base desvenlafaxine
WO2009072334A1 (fr) Particule de cœur pour préparation pharmaceutique
WO2009052353A3 (fr) Formulations pharmaceutiques de trospium
WO2007145863A3 (fr) Formulation à libération prolongée de naltréxone
WO2008056375A3 (fr) Formulations pharmaceutiques comprenant du valsartan
WO2008077813A3 (fr) Comprimés se désintégrant oralement
WO2006096194A8 (fr) Formulations a liberation immediate de formes de dosage oral de memantine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08807003

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08807003

Country of ref document: EP

Kind code of ref document: A2